Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Combination Therapy in Advanced Solid Tumors
NCT06015048Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in solid tumor (advanced stage), sponsored by Hengrui. Started Aug 2023; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06015048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015048.